抗ウイルス剤併用療法の世界市場レポート 2025年

抗ウイルス剤併用療法市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は7.6%で769億2,000万米ドルに成長します。予測期間の成長は、ウイルスの脅威の継続、研究開発投資、世界ヘルスへの備え、患者中心のアプローチ、新たなウイルス適応症への拡大の可能性などに起因すると考えられます。予測期間の主な動向には、ナノテクノロジーの統合、革新的な組み合わせの臨床試験、研究開発のための共同研究、創薬における人工知能の応用、薬剤耐性を克服するための戦略などがあります。

ウイルス性疾患の急増は、今後数年間における抗ウイルス剤併用療法市場の拡大を促進します。ウイルスとして知られる微小な感染因子に起因するウイルス性疾患は、効果的な治療アプローチが必要です。抗ウイルス剤の併用療法は、薬剤耐性のリスクを軽減し、治療効率を高める上で重要な役割を果たしています。例えば、2022年6月現在、世界保健機関（WHO）は、B型肝炎またはC型肝炎の感染者は世界で3億5,400万人に上り、C型肝炎の新規感染者は年間150万人に上ると報告しています。このようなウイルス感染の急増は、深刻化する健康課題に対処するための高度な抗ウイルス剤併用療法の必要性を強調しています。

個別化医療に対する需要の高まりは、抗ウイルス剤併用療法市場の成長を促進します。個人の遺伝子やタンパク質の構成に合わせた個別化医療は、病気の予防、発見、治療に革命をもたらします。遺伝子組成の個人差は抗ウイルス療法への反応に影響するため、これらの違いを特定し、治療戦略を最適化する必要があります。例えば、2022年に米国食品医薬品局（FDA）は12の個別化医薬品を認可しました。これは、個別化医療連合（Personalized Medicine Coalition）が強調しているように、新たに承認されたすべての治療用分子実体の約34％を占める。この急増する需要は、治療アプローチを調整することの重要性を強調し、抗ウイルス剤併用療法市場の台頭を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界抗ウイルス剤併用療法PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の抗ウイルス剤併用療法市場：成長率分析
• 世界の抗ウイルス剤併用療法市場の実績：規模と成長, 2019-2024
• 世界の抗ウイルス剤併用療法市場の予測：規模と成長, 2024-2029, 2034F
• 世界抗ウイルス剤併用療法総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗ウイルス剤併用療法市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブランド
• ジェネリック
• 世界の抗ウイルス剤併用療法市場薬剤の組み合わせによる、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヌクレオチド逆転写酵素阻害剤/非ヌクレオチド逆転写酵素阻害剤
• インテグラーゼ阻害剤/ヌクレオチド逆転写酵素阻害剤
• ヌクレオチド逆転写酵素阻害剤
• ヌクレオチド逆転写酵素阻害剤/プロテアーゼ阻害剤
• その他の薬剤の組み合わせ
• 世界の抗ウイルス剤併用療法市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• 世界の抗ウイルス剤併用療法市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の流通チャネル
• 世界の抗ウイルス剤併用療法市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒト免疫不全ウイルス
• 肝炎
• その他の適応症
• 世界の抗ウイルス剤併用療法市場、ブランド別サブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単一ブランドの組み合わせ
• ブランド認知度の高い併用療法
• 世界の抗ウイルス剤併用療法市場、ジェネリックのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリック固定用量配合剤
• 同様の効能を持つジェネリック医薬品の組み合わせ

第7章 地域別・国別分析

• 世界の抗ウイルス剤併用療法市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の抗ウイルス剤併用療法市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗ウイルス剤併用療法市場：競合情勢
• 抗ウイルス剤併用療法市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Celltrion Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Cipla Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Janssen Global Services LLC
• Merck & Co. Inc.
• Mylan N.V.
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Limited
• Novartis International AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Atea Pharmaceuticals Inc.
• AstraZeneca plc
• Eli Lilly and Company
• Moderna Inc.
• Regeneron Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗ウイルス剤併用療法市場2029：新たな機会を提供する国
• 抗ウイルス剤併用療法市場2029：新たな機会を提供するセグメント
• 抗ウイルス剤併用療法市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Antiviral combination therapy is a strategic approach involving the use of multiple antiviral medications to effectively address viral infections. This method enhances treatment outcomes by targeting various stages of the virus's life cycle, ultimately minimizing the risk of drug resistance.

The primary categories of antiviral combination therapy are branded and generic. Branded antiviral combination therapies are medications manufactured and marketed under a specific brand name by the manufacturer, holding regulatory approval through a new drug application. These formulations typically consist of a combination of two or more antiviral agents and are employed in treating diverse viral infections, including Human Immunodeficiency Virus (HIV), hepatitis C, and influenza. Examples of branded antiviral combination therapies include Atripla, Harvoni, Complera, Symfi Lo, and Xofluza. These combinations incorporate various drug classes, such as nucleotide reverse transcriptase inhibitors, non-nucleotide reverse transcriptase inhibitors, integrase inhibitors, nucleotide reverse transcriptase inhibitors, and protease inhibitors. They are administered through oral and intravenous routes and are distributed through hospital pharmacies, retail pharmacies, and other channels for the treatment of human immunodeficiency virus, hepatitis, and other viral indications.

The antiviral combination therapy market research report is one of a series of new reports from The Business Research Company that provides antiviral combination therapy market statistics, including the antiviral combination therapy industry's global market size, regional shares, competitors with an antiviral combination therapy market share, detailed antiviral combination therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the antiviral combination therapy industry. This antiviral combination therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antiviral combination therapy market size has grown strongly in recent years. It will grow from$53.86 billion in 2024 to $57.3 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to risen viral infections, patient preference for combination treatments, emergence of drug resistance, advancements in virology and immunology, global healthcare initiatives

The antiviral combination therapy market size is expected to see strong growth in the next few years. It will grow to $76.92 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to continued viral threats, research and development investments, global health preparedness, patient-centric approaches, potential expansion to new viral indications. Major trends in the forecast period include integration of nanotechnology, clinical trials for innovative combinations, collaborations for research and development, application of artificial intelligence in drug discovery, strategies for overcoming drug resistance.

The surge in viral diseases' occurrences is poised to drive the expansion of the antiviral combination therapy market in the forthcoming years. Viral diseases, stemming from microscopic infectious agents known as viruses, necessitate effective treatment approaches. Antiviral combination therapies play a crucial role in mitigating drug resistance risks and bolstering treatment efficiency. For instance, as of June 2022, the World Health Organization (WHO) reported a staggering 354 million individuals globally afflicted by hepatitis B or C infections, with an annual influx of 1.5 million new hepatitis C cases. This surge in viral infections underscores the imperative for advanced antiviral combination therapies to address these escalating health challenges.

The escalating demand for personalized medicine is set to fuel the growth of the antiviral combination therapy market. Personalized medicine, tailored to an individual's genetic or protein makeup, revolutionizes disease prevention, detection, and treatment. Variances in genetic compositions among individuals influence responses to antiviral therapies, prompting the need to identify these distinctions and optimize treatment strategies. For instance, in 2022, the US Food and Drug Administration (FDA) greenlit 12 personalized medicines, constituting roughly 34% of all newly approved therapeutic molecular entities, as highlighted by the Personalized Medicine Coalition. This burgeoning demand underscores the significance of tailoring treatment approaches, fostering the rise of the antiviral combination therapy market.

The market for antiviral combination therapy sees a rising focus on product innovation. Key companies are actively engaged in developing novel technological solutions to fortify their market standing. Gilead Sciences, Inc., a US-based biopharmaceutical firm, received FDA approval in December 2022 for Sunlenca (lenacapavir) in combination with other antiretroviral(s) to treat heavily treatment-experienced (HTE) adults with multi-drug-resistant (MDR) HIV-1 infection.

Major companies in the antiviral combination therapy market are concentrating on innovative solutions, such as antiviral therapies, to enhance treatment efficacy, improve patient outcomes, and tackle the increasing challenge of viral resistance. Antiviral therapies are treatments aimed at inhibiting the development or replication of viruses, thus managing viral infections. For example, in October 2023, Gilead Sciences, Inc., a biopharmaceutical company based in the US, formed a partnership with Assembly Biosciences Inc., a US-based biotechnology company, to develop innovative antiviral therapeutics aimed at serious viral diseases. This collaboration is focused on the research and development of novel antiviral therapies, initially concentrating on Assembly Bio's established areas, which include herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV).

In February 2023, Tonix Pharmaceuticals Holding Corporation, a US-based pharmaceutical company specializing in the development of novel therapies and vaccines for central nervous system disorders and infectious diseases, successfully acquired a preclinical infectious disease portfolio from Healion Bio Inc. for $1.2 million. This strategic acquisition is aimed at expanding Tonix Pharmaceuticals' overall portfolio, incorporating a range of next-generation antiviral technology assets. The newly acquired assets include a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action. These candidates can be utilized either as monotherapy or in combination with other antivirals. Healion Bio Inc., the source of the acquired portfolio, is a US-based biotechnology company dedicated to the manufacturing and development of medicines for the treatment and prevention of infectious diseases.

Major companies operating in the antiviral combination therapy market include AbbVie Inc., Bristol-Myers Squibb Company, Celltrion Inc., Cipla Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Janssen Global Services LLC, Merck & Co. Inc., Mylan N.V., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Novartis International AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Atea Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, Moderna Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vir Biotechnology Inc., Johnson & Johnson, Roche Holding AG, Sun Pharmaceutical Industries Ltd., Hetero Drugs Limited, Macleods Pharmaceuticals Ltd., Emcure Pharmaceuticals Ltd., AuroMedics Pharma LLC, Alembic Pharmaceuticals Limited, Zydus lifescience Ltd., Strides Pharma Science Limited, Glenmark Pharmaceuticals Inc., Lupin Pharmaceuticals Inc.

North America was the largest region in the antiviral combination therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global antiviral combination therapy market report during the forecast period. The regions covered in the antiviral combination therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antiviral combination therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The antiviral combination therapy market consists of sales of protease inhibitors, reverse transcriptase inhibitors and integrase inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antiviral Combination Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antiviral combination therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antiviral combination therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antiviral combination therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Branded; Generic
• 2) By Drug Combination: Nucleotide Reverse Transcriptase Inhibitors/Non-Nucleotide Reverse Transcriptase Inhibitors; Integrase Inhibitor/Nucleotide Reverse Transcriptase Inhibitors; Nucleotide Reverse Transcriptase Inhibitors; Nucleotide Reverse Transcriptase Inhibitors/Protease Inhibitor; Other Drug Combinations
• 3) By Route Of Administration: Oral; Intravenous
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• 5) By Indication: Human Immunodeficiency Virus; Hepatitis; Other Indications
• Subsegments:
• 1) By Branded: Single Brand Combinations; Combination Therapies With Brand Recognition
• 2) By Generic: Generic Fixed-Dose Combinations; Generic Drug Combinations With Similar Efficacy
• Companies Mentioned: AbbVie Inc.; Bristol-Myers Squibb Company; Celltrion Inc.; Cipla Inc.; F. Hoffmann-La Roche Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antiviral Combination Therapy Market Characteristics

3. Antiviral Combination Therapy Market Trends And Strategies

4. Antiviral Combination Therapy Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Antiviral Combination Therapy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antiviral Combination Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antiviral Combination Therapy Market Growth Rate Analysis
• 5.4. Global Antiviral Combination Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antiviral Combination Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antiviral Combination Therapy Total Addressable Market (TAM)

6. Antiviral Combination Therapy Market Segmentation

• 6.1. Global Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded
• Generic
• 6.2. Global Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nucleotide Reverse Transcriptase Inhibitors/Non-Nucleotide Reverse Transcriptase Inhibitors
• Integrase Inhibitor/Nucleotide Reverse Transcriptase Inhibitors
• Nucleotide Reverse Transcriptase Inhibitors
• Nucleotide Reverse Transcriptase Inhibitors/Protease Inhibitor
• Other Drug Combinations
• 6.3. Global Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• 6.4. Global Antiviral Combination Therapy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• 6.5. Global Antiviral Combination Therapy Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human Immunodeficiency Virus
• Hepatitis
• Other Indications
• 6.6. Global Antiviral Combination Therapy Market, Sub-Segmentation Of Branded, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Brand Combinations
• Combination Therapies With Brand Recognition
• 6.7. Global Antiviral Combination Therapy Market, Sub-Segmentation Of Generic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Fixed-Dose Combinations
• Generic Drug Combinations With Similar Efficacy

7. Antiviral Combination Therapy Market Regional And Country Analysis

• 7.1. Global Antiviral Combination Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antiviral Combination Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antiviral Combination Therapy Market

• 8.1. Asia-Pacific Antiviral Combination Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antiviral Combination Therapy Market

• 9.1. China Antiviral Combination Therapy Market Overview
• 9.2. China Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antiviral Combination Therapy Market

• 10.1. India Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antiviral Combination Therapy Market

• 11.1. Japan Antiviral Combination Therapy Market Overview
• 11.2. Japan Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antiviral Combination Therapy Market

• 12.1. Australia Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antiviral Combination Therapy Market

• 13.1. Indonesia Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antiviral Combination Therapy Market

• 14.1. South Korea Antiviral Combination Therapy Market Overview
• 14.2. South Korea Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antiviral Combination Therapy Market

• 15.1. Western Europe Antiviral Combination Therapy Market Overview
• 15.2. Western Europe Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antiviral Combination Therapy Market

• 16.1. UK Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antiviral Combination Therapy Market

• 17.1. Germany Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antiviral Combination Therapy Market

• 18.1. France Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antiviral Combination Therapy Market

• 19.1. Italy Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antiviral Combination Therapy Market

• 20.1. Spain Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antiviral Combination Therapy Market

• 21.1. Eastern Europe Antiviral Combination Therapy Market Overview
• 21.2. Eastern Europe Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antiviral Combination Therapy Market

• 22.1. Russia Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antiviral Combination Therapy Market

• 23.1. North America Antiviral Combination Therapy Market Overview
• 23.2. North America Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antiviral Combination Therapy Market

• 24.1. USA Antiviral Combination Therapy Market Overview
• 24.2. USA Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antiviral Combination Therapy Market

• 25.1. Canada Antiviral Combination Therapy Market Overview
• 25.2. Canada Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antiviral Combination Therapy Market

• 26.1. South America Antiviral Combination Therapy Market Overview
• 26.2. South America Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antiviral Combination Therapy Market

• 27.1. Brazil Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antiviral Combination Therapy Market

• 28.1. Middle East Antiviral Combination Therapy Market Overview
• 28.2. Middle East Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antiviral Combination Therapy Market

• 29.1. Africa Antiviral Combination Therapy Market Overview
• 29.2. Africa Antiviral Combination Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antiviral Combination Therapy Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antiviral Combination Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antiviral Combination Therapy Market Competitive Landscape And Company Profiles

• 30.1. Antiviral Combination Therapy Market Competitive Landscape
• 30.2. Antiviral Combination Therapy Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Celltrion Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Cipla Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Antiviral Combination Therapy Market Other Major And Innovative Companies

• 31.1. Gilead Sciences Inc.
• 31.2. GlaxoSmithKline plc
• 31.3. Janssen Global Services LLC
• 31.4. Merck & Co. Inc.
• 31.5. Mylan N.V.
• 31.6. Aurobindo Pharma Limited
• 31.7. Dr. Reddy's Laboratories Limited
• 31.8. Novartis International AG
• 31.9. Pfizer Inc.
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Atea Pharmaceuticals Inc.
• 31.12. AstraZeneca plc
• 31.13. Eli Lilly and Company
• 31.14. Moderna Inc.
• 31.15. Regeneron Pharmaceuticals Inc.

32. Global Antiviral Combination Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antiviral Combination Therapy Market

34. Recent Developments In The Antiviral Combination Therapy Market

35. Antiviral Combination Therapy Market High Potential Countries, Segments and Strategies

• 35.1 Antiviral Combination Therapy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antiviral Combination Therapy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antiviral Combination Therapy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer